PATH

Cancer is one of Europe’s leading health burdens, responsible for 26% of all deaths in 2021, with mortality expected to rise by 24% by 2035 and an economic impact exceeding €100 billion annually. Despite the ambitions of Europe’s Beating Cancer Plan, integrating complex cancer data across systems remains a major obstacle. The European Health Data Space (EHDS) seeks to address these gaps, though challenges around interoperability, privacy, and infrastructure persist. In this context, PATH will transform cancer care by leveraging secure data exchange and digital technologies to improve early detection, diagnosis, treatment, and long-term patient outcomes. Through the integration of AI tools into clinical workflows, PATH will foster a safe, ethical, and sustainable healthcare ecosystem aligned with the Beating Cancer Plan and the EHDS. The project will create a federated, privacy-preserving health data space supporting interoperability and data fairness. AI models will be trained on representative, FAIR-compliant datasets with builtin transparency and bias mitigation. Federated learning and Trusted Execution Environments will enable secure, real-world model refinement while preserving patient privacy. An AI-powered dashboard will connect clinicians, patients, and developers to deploy validated tools and ensure broad adoption. To ensure long-term impact, PATH will conduct EU-wide pilot studies evaluating clinical outcomes, survivability, efficiency, and cost-effectiveness. It will also establish scalable business models, promote digital literacy among healthcare professionals, and drive cross-sector collaboration for responsible, evidence-based AI integration across Europe’s cancer care continuum. Delivering this level of clinical, technological, and systemic transformation requires close and sustained collaboration across the entire cancer care and innovation ecosystem. By bringing together the complementary missions, expertise, and capacities of public actors and private companies, the PATH Public–Private Partnership (PPP) composed of 24 partners provides the structural foundation needed to align research excellence, clinical practice, industrial innovation, and policy objectives. The PPP ensures that PATH solutions are simultaneously scientifically robust, clinically relevant, technologically advanced, and economically sustainable. Moreover, this collaborative framework enhances trust, accelerates knowledge transfer, and supports the translation of innovation from research to realworld healthcare environments—thereby enabling PATH to achieve measurable, scalable, and lasting impact across Europe.

Consortium

EUROPEAN DYNAMICS LUXEMBOURG SA (ED), LU
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON (UOA), GR
IDRYMA TECHNOLOGIAS KAI EREVNAS (ITE), GR
AGORA LABS S.R.L. (AGORA), IT
WELLICS LTD (WELLICS), UK
AINIGMA TECHNOLOGIES (AINIG), BE
TIMELEX (TIM), PIC 991228063, BE
ARISTOTELIO PANEPISTIMIO THESSALONIKIS (AUTH), GR
CENTRO REGIONALE INFORMATION E COMMUNICATION TECHNOLOGY SCRL (CERIC), IT
TECHNOLOGIKO PANEPISTIMIO KYPROU (CUT), CY
SHINE 2EUROPE LDA (SHINE), P
UNIVERZITET U NOVOM SADU FAKULTET TEHNICKIH NAUKA (FTN), SRB
UNIVERSITY OF NOVI SAD, FACULTY OF MEDICINE NOVI SAD (MFUNS), SRB
ANCORA HEALTH BV (AH), NL
UNIVERSITEIT MAASTRICHT (UMAAS), NL
Hict (HICT), PIC 895151115, BE
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS (CERTH), GR
FWDFASTER AI Research BV (Fwd), NL
PAGKYPRIOS SYNDESMOS KARKINOPATHON KAI FILON 1986 (PASYKAF), CY
LINAC-PET SCAN OPCO LIMITED (LINAC), CY
GENIKO NOSOKOMEIO PAPAGEORGIOU (GHPAP), GR
PANEPISTIMIAKO GENIKO NOSOKOMEIO IRAKLEIOU (PAGNI), GR
REGION SORMLAND (SOEN), SE